- page

Scroll to explore

Scroll back top

Happy New Year from all of us at Domain Therapeutics !

29 October 2024

Labiotech – GPCR therapies: Eight promising biotechs hacking the cell signaling pathway

23 October 2024

Prix Galien USA: Domain Therapeutics Nominated for the Prestigious Best Startup Award

Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR...

Oncologypipeline – CCR8 expectations

Domain Therapeutics appoints Sean A. MacDonald as Chief Executive Officer

Domain Therapeutics to participate at premier investor and healthcare conferences

Domain Therapeutics to present latest data on DT-9045, a first-in-class Negative Allosteric Modulat...

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 ...

27 February 2024

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)